EVDI Drug Patent Profile

Name: EVDI Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

When do Evdi patents expire, and when can generic versions of Evdi launch?

Evdi is a drug marketed by Apotex and is included in one NDA. There is one patent protecting this drug.

This drug has one patent family member in one country.

The generic ingredient in EVDI is trabectedin. There are four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the trabectedin profile page.

DrugPatentWatch^® Generic Entry Outlook for Evdi

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 18, 2043. This may change due to patent challenges or generic licensing.

There is one tentative approval for the generic drug (trabectedin), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

< Available with Subscription >

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for EVDI?
What are the global sales for EVDI?
What is Average Wholesale Price for EVDI?

Summary for EVDI

International Patents:	1
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
What excipients (inactive ingredients) are in EVDI?	EVDI excipients list
DailyMed Link:	EVDI at DailyMed

Drug patent expirations by year for EVDI

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for EVDI

Generic Entry Date for EVDI^: ⤷ Start Trial* Constraining patent/regulatory exclusivity: ⤷ Start Trial NDA: 220837 Dosage: SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for EVDI

Drug Class	Alkylating Drug
Mechanism of Action	Alkylating Activity

US Patents and Regulatory Information for EVDI

EVDI is protected by one US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of EVDI is ⤷ Start Trial.

This potential generic entry date is based on patent ⤷ Start Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apotex	EVDI	trabectedin	SOLUTION;INTRAVENOUS	220837-001	May 1, 2026		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y			⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for EVDI

When does loss-of-exclusivity occur for EVDI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

European Patent Office

Patent: 15184
Patent: COMPOSITION DE TRABECTÉDINE (TRABECTEDIN COMPOSITION)
Estimated Expiration: ⤷ Start Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering EVDI around the world.

Subscribe to access the full database, or Start Trial
Country	Patent Number	Title	Estimated Expiration
European Patent Office	4215184	COMPOSITION DE TRABECTÉDINE (TRABECTEDIN COMPOSITION)	⤷ Start Trial
>Country	>Patent Number	>Title	>Estimated Expiration